

**Amendments to the Drawings:**

Please replace "Figure 1" as filed and appearing on page 25 of the application with amended "Figure 1" appearing on the attached "Replacement Sheet." The only changes that have been made to the Figure as filed are to: a) insert sequence identifiers (SEQ ID NO:1-SEQ ID NO:7); b) renumber the sheet as "1/1;" c) reduce the size of the figure somewhat to allow for the insertion of the sequence identifiers; and d) reposition the Figure on the page.

**Amendments to the Sequence Listing:**

Please delete the Sequence Listing presently in the application. Please enter the substitute Sequence Listing enclosed herewith on separate pages following the claims and abstract of the application. A computer readable form of the Sequence Listing in ASCII text is also enclosed. The sequence listing has been amended to include SEQ ID NO:7-SEQ ID NO:13. No other substantive changes were made.

## **Remarks**

### **I. Status of the Application and Claims**

All of the claims pending in the present application have been cancelled herein and new claims 60-74 have been introduced. One of these, claim 75, is in a non-elected restriction group and is therefore withdrawn. Thus, the claims now pending are claims 60-74

### **II. The Amendments**

Figure 1 of the application was amended to include sequence identification numbers for each of the peptides shown and the sequence listing was amended to include each of these peptides. No other substantive changes were made to either the figure or sequence listing.

Claims were amended to restrict them to peptides based upon SEQ ID NO:4 and, for the most part, are fully supported by the original claims. Support for new claims 67 and 68 may be found on page 4 of the application, lines 1-8.

The amendments made herein do not add new matter to the application and their entry is therefore respectfully requested.

### **III. Compliance with Sequence Listing Requirements**

On page 1 of the Office Action, the Examiner indicates that Applicants failed to comply with the requirements of 37 CFR §§1.821-1.825 because did not include the peptides shown in figure 1 in the filed sequence listing and did not provide sequence identification numbers for these peptides.

In response, Applicants have amended Figure 1 so that all of the peptides shown therein now have a sequence identification number. They have also amended the sequence listing to include the peptides from the figure.

### **Statements to Comply with Sequence Listing Rules**

In compliance with 37 C.F.R. § 1.821(f), Applicants' undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted herewith are the same. In accordance with 37 C.F.R. § 1.821(g), Applicants'

undersigned attorney hereby states that the Sequence Listing submitted herewith does not add new matter to the application.

In light of the above amendments and statements, Applicants respectfully submit that the sequence listing requirements for patent applications have now been met.

#### **IV. Claim Objections**

On page 2 of the Office Action, the Examiner objects to claims 1, 2, 49-51 and 58 for not falling within the scope of Applicants' elected restriction group.

In response, Applicants have introduced amended claims and believe that all of these are now properly within the elected group.

#### **The Rejections**

On pages 2-3 of the Office Action, all pending claims are rejected under 35 USC §112, first paragraph, for allegedly failing to meet the enablement requirement of patentability. In making the rejection, the Examiner indicates that "Claims directed toward a peptide of 15-30 amino acids in length comprising SEQ ID NO:4 wherein the tyrosine residues at amino acids 19-21 must be present would be acceptable."

In response, Applicants have amended claims so that they are of a scope commensurate with what the Examiner has indicated should be acceptable. It is therefore respectfully submitted that the Examiner's rejection has been overcome.

#### **Conclusion**

In light of the considerations above, Applicants respectfully submit that all of the Examiner's rejections have been overcome. It is therefore requested that these rejections be withdrawn and that the claims presently pending in the application be allowed.

If, in the opinion of the Examiner, a phone call may help to expedite the prosecution of this application, the Examiner is invited to call Applicants' undersigned attorney at (240)683-6165.

Respectfully submitted,

LAW OFFICE OF MICHAEL A. SANZO

By: Michael A. Sanzo

Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date: January 2, 2008  
15400 Calhoun Drive, Suite 125  
Rockville, Md. 20855  
(240)683-6165